


Wogonoside Datasheet

4th Edition (Revised in July, 2016)

[Product Information]

Name: Wogonoside**Catalog No.:** CFN99710**Cas No.:** 51059-44-0**Purity:** > 98%**M.F:** C₂₂H₂₀O₁₁**M.W:** 460.39**Physical Description:** Yellow cryst.

Synonyms: Glychionide B; Oroxindin; Wogonin 7-O-glucuronide; Wogonin 7-glucuronide; 5-Hydroxy-8-methoxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl-beta-D-glucopyranosiduronic acid.



[Intended Use]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

[Source]

The herbs of *Scutellaria baicalensis* Georgi.

[Biological Activity or Inhibitors]

Wogonoside, the glucuronide metabolite of wogonin, has anti-inflammatory, anti-angiogenic and anticancer effects, it may exert its anti-inflammatory effect via dual inhibition of NF- κ B and NLRP3 inflammasome, suggests that wogonoside might be a potential effective drug for inflammatory bowel diseases.^[1]

Wogonoside, isolated from *Scutellaria baicalensis*, it markedly inhibits histamine release in cells stimulated with calcium ionophore A23187 or compound 48/80 and markedly inhibits LTB₄ production at the concentration of 100 μ M.^[2]

Wogonoside inhibits lipopolysaccharide-induced angiogenesis in vitro and in vivo via toll-like receptor 4 signal transduction, and that it might have a therapeutic potential for the diseases associated with the development of both inflammation and progress.^[3]

Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in acute myeloid leukemia (AML) cells, it may represent a therapeutic candidate for the treatment of AML.^[4]

Wogonoside partially inhibits MDA-MB-231 cell growth by inducing autophagy through the MAPK-mTOR pathway and may be a promising anti-tumor agent.^[5]

Wogonoside inhibits thrombin-catalyzed fibrin polymerization and platelet aggregation, it also elicits anticoagulant effects in mice, it possesses antithrombotic activities and offers a basis for development of a novel anticoagulant.^[6]

[Solvent]

Pyridine, DMSO, Methanol, Ethanol, Hot water, etc.

[HPLC Method]^[7]

Mobile phase: Acetonitrile- Phosphate buffer, gradient elution ;

Flow rate: 1.5 ml/min;

Column temperature: Room Temperature;

The wave length of determination: 276 nm.

[Storage]

2-8°C, Protected from air and light, refrigerate or freeze.

[References]

- [1] Sun Y, Zhao Y, Yao J, *et al. Biochem. Pharmacol.*, 2015, 94(2):142-54.
- [2] Lim B O. *J. Ethnopharmacol.*, 2003, 84(1):23-9.
- [3] Chen Y, Lu N, Ling Y, *et al. Toxicology*, 2009, 259(1–2):10-7.
- [4] Chen Y, Hui H, Yang H, *et al. Blood*, 2013, 121(18):3682-91.
- [5] Sun Y, Zou M, Chen H, *et al. Food Chem. Toxicol. A*, 2012, 51(1):53-60.
- [6] Ku S K, Bae J S. *Fitoterapia*, 2014, 98:27-35.
- [7] Lu T, Song J, Lin X, *et al. Chinese Traditional & Herbal Drugs*, 2005, 36(6):870-3.

[Contact]

Address:

S5-3 Building, No. 111, Dongfeng Rd.,
Wuhan Economic and Technological Development Zone,
Wuhan, Hubei 430056,
China

Email: info@chemfaces.com

Tel: +86-27-84237783

Fax: +86-27-84254680

Web: www.chemfaces.com

Tech Support: service@chemfaces.com